A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients

Trial Profile

A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs CFZ 533 (Primary) ; CFZ 533 (Primary) ; Corticosteroids; Mycophenolic acid; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Mar 2018 Status changed from recruiting to completed.
    • 26 Jan 2018 This trial was completed in Netherlands(End date: 2017-11-29), according to European Clinical Trials Database.
    • 12 Jan 2018 This trial was discontinued in Germany (End date: 2017-11-29), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top